

Hassane M Zarour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8390065/publications.pdf>

Version: 2024-02-01

25
papers

3,314
citations

516561

16
h-index

642610

23
g-index

29
all docs

29
docs citations

29
times ranked

5702
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	3.8	857
2	Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. <i>Science</i> , 2021, 371, 595-602.	6.0	746
3	TIGIT in cancer immunotherapy. , 2020, 8, e000957.		382
4	Reversing T-cell Dysfunction and Exhaustion in Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1856-1864.	3.2	317
5	Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1845-1855.	3.2	242
6	Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. <i>Nature Medicine</i> , 2022, 28, 545-556.	15.2	167
7	IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. <i>Cancer Research</i> , 2015, 75, 1635-1644.	0.4	145
8	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 5520-5533.	3.2	88
9	IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. <i>Cancer Immunology Research</i> , 2019, 7, 1258-1266.	1.6	56
10	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3450-3458.	0.8	55
11	Immunotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 2-14.	1.3	53
12	Tim-3 mediates T cell trogocytosis to limit antitumor immunity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	25
13	Cancer immunotherapy: Progress and challenges in the clinical setting. <i>European Journal of Immunology</i> , 2011, 41, 1510-1515.	1.6	24
14	Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3054-3054.	0.8	24
15	Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 4370-4384.	3.2	15
16	Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors. <i>Methods in Molecular Biology</i> , 2020, 2055, 23-60.	0.4	12
17	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. <i>Oncolimmunology</i> , 2021, 10, 1898105.	2.1	11
18	Targeting novel inhibitory receptors in cancer immunotherapy. <i>Seminars in Immunology</i> , 2020, 49, 101436.	2.7	8

#	ARTICLE	IF	CITATIONS
19	Association of medication (Med) and antibiotic (Abx) use with response and survival in advanced melanoma (MEL) receiving PD-1 inhibitors.. Journal of Clinical Oncology, 2019, 37, 9572-9572.	0.8	7
20	scMAPA: Identification of cell-typeâ€“specific alternative polyadenylation in complex tissues. GigaScience, 2022, 11, .	3.3	4
21	Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors.. Journal of Clinical Oncology, 2019, 37, 9579-9579.	0.8	1
22	The cancerâ€“germline antigen TRACâ€“3 stimulates Th1â€“type, Tollâ€“like receptor 8â€“negative antigenâ€“specific CD4+ regulatory T cells. FASEB Journal, 2008, 22, 1079.19.	0.2	0
23	Upregulation of PDâ€“1 expression on tumor antigenâ€“specific CD8+ T cells in patients with advanced melanoma is associated with reversible immune dysfunction. FASEB Journal, 2008, 22, 1077.21.	0.2	0
24	Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, e15175-e15175.	0.8	0
25	The microbiome: a basis for novel immunomodulation in mice and men. Clinical Advances in Hematology and Oncology, 2017, 15, 535-536.	0.3	0